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Multivalentreadth, and durability of neutralizing antibody responses to HIV are major
challenges for HIV vaccine development. To address these challenges, the studies described evaluate in
rabbits the titers, breadth, and epitope speciﬁcities of antibody responses elicited by HIV envelope subunit
vaccines adjuvanted with MF59 with or without CpG oligodeoxynucleotide (ODN). Animals were immunized
with trimeric o-gp140ΔV2 derived from subtype B HIV-1SF162 or subtype C HIV-1TV1, or proteins from both
strains. Immunization with SF162 or TV1 with MF59/CpG elicited higher titers of binding and neutralizing
antibodies to SF162 than monovalent immunization with MF59 alone (Pb0.01). Bivalent immunization
increased binding and neutralizing antibody titers over single envelope immunization in MF59 (Pb0.01).
Bivalent immunization also improved neutralization breadth. Epitope mapping indicated neutralizing
activity in rabbits was directed to V3 and V4. Overall, our data suggests that a multivalent vaccination
approach with MF59 and CpG can enhance humoral responses to HIV-1.
© 2009 Elsevier Inc. All rights reserved.Introduction
Subunit vaccines consisting of highly puriﬁed viral proteins have
become increasingly prominent, but are often not adequately
immunogenic. An attractive approach currently receiving increased
attention is to improve the immunogenicity of subunit vaccines by
formulation with immune stimulatory adjuvants. These adjuvant
formulations serve to accelerate, prolong and/or enhance the quality
and magnitude of immune responses to co-administered antigen
preparations. Adjuvants have been classiﬁed as either immune
potentiators or delivery systems (Pashine et al., 2005) and some
appear to serve both roles. Immune potentiators were deﬁned as
compounds able to trigger innate immune responses and generate
robust and long-lasting adaptive responses. Use of a delivery system
might then serve to target the antigen and immune potentiator to the
desired cells for optimal stimulation. Since adjuvants can be deﬁned
by and work through differing mechanisms of action, the key is to
select an adjuvant(s) based on the route of immunization as well as
the type of response preferred, such as Th1- or Th2-type actions. The
desired effect can be accomplished via a variety of mechanisms. Somearnett).
College London, Chelsea and
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ll rights reserved.adjuvants are able to associate with and facilitate transport and
delivery of antigen to an antigen presenting cell (APC). Others are able
to inﬂuence antigen processing and presentation by APCs, and
therefore MHC speciﬁcity. Adjuvants can also increase the half life of
antigens in vivo leading to a prolonged immune response. Therefore,
an ideal vaccine would consist of an optimized formulation of antigen,
immune potentiator, and delivery system. Speciﬁcally, the present
study focuses on the capability of adjuvant combinations to enhance
the immunogenicity of HIV-1 envelope subunit vaccines, with respect
to the generation of potent and broad humoral responses.
Previous studies indicated that adjuvant formulations can
dramatically inﬂuence the types of antibodies that are generated
in response to HIV and other antigens. In one study, administration
of an HIV-1 gp120 envelope (Env) protein formulated with alum
elicited a Th2 response and IgG1 antibodies (Javaherian et al., 1990).
However, the same vaccine antigen with the immune potentiator IL-
12 induced a Th1 response and IgG2 and IgG3 antibody isotypes.
The inclusion of immune potentiators has the capability to increase
not only serum antibody levels, but also antibodies with improved
functional attributes. For example, serum anti-Env avidity was
increased when using granulocyte–macrophage-colony stimulating
factor (GM-CSF) as an immune potentiator (Lai et al., 2007). GM-
CSF was also found to be able to inﬂuence the neutralizing breadth
of antibodies (Robinson et al., 2006). In this study, only serum from
animals that included GM-CSF as part of the formulation were able
to neutralize the isolate 89.6P.
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deoxycytosine-deoxyguanosine (CpG) motifs, or CpG ODNs, are TLR9
agonists that have also been shown to be effective in enhancing
antibody potency as immune potentiators. In the case of the highly
efﬁcacious hepatitis B surface antigen (HBsAg) vaccine, a CpG plus
alum combination was able to increase antibody avidity to HBsAg and
also increased the proportion of high avidity antibodies (Siegrist et al.,
2004). CpG is of particular interest as it can directly activate not only
dendritic cells (DC), but B cells as well. In particular, CpG preferentially
acts on B cell populations that predominantly express TLR9, those
being activated and memory B cells. CpG enacts the innate immune
response via enhancing the activation and presentation function of
DCs. This makes CpG an especially desirable component of a vaccine
given that strong stimulation of the innate immune response appears
important for the evolution and generation of robust adaptiveFig. 1. Vaccine induced envelope-speciﬁc antibody responses in rabbit sera. Rabbits were imm
in MF59 in the presence or absence of CpG. Two weeks following the third (p3) and fourth
values calculated. (A) Titers of serum antibodies to SF162 gp140ΔV2 (top panel) and TV1 gp1
gp140ΔV2. (C) Avidity of SF162 gp140ΔV2-speciﬁc antibodies.immune responses. This response then could be maximized by
colocalization and efﬁcient delivery of CpG and antigen to DCs by
using the oil-emulsion MF59, which has been shown to be
internalized by DCs and macrophages into endosomal vesicles and
to cause secretion of cytokines known to recruit immune cells from
the blood into tissue as well as increase endocytic uptake (Dupuis
et al., 1998, 2001; Seubert et al., 2008). The combination of CpG and
MF59 with antigen could therefore enhance endosomal uptake and
facilitate the interaction of CpG with TLR9 in the endocytic vesicles
and enhance antigen presentation by DCs. Enhanced DC activation and
maturation may lead to enhanced antibody responses and increase
the size of the memory B cell pool. The current study seeks to
determine whether the formulation of MF59 and the immune
potentiator CpG 7909, administered with well-characterized HIV-1
trimeric (o-)gp140ΔV2 envelope proteins would serve to enhanceunized with SF162 o-gp140ΔV2, TV1 o-gp140ΔV2, or a combination of both envelopes
(p4) immunizations, individual sera were analyzed via ELISA and the group geomean
40ΔV2 (bottom panel). (B) Ratio of serum antibodies to native versus denatured SF162
149B. Burke et al. / Virology 387 (2009) 147–156humoral responses in rabbits over antigen formulated using the
potent MF59 alone.
Beyond the issues related to elicitation of potent and durable
immunity against HIV by virtue of using optimal adjuvant formula-
tions, a major obstacle to achieving a viable HIV vaccine is the
enormous degree of sequence diversity encountered in circulating
virus strains. Moreover, known conserved conformational epitopes
that could prove to be useful targets for inclusion in a vaccine are
cryptic, discontinuous, and relatively non-immunogenic. Thus, one
promising approach to overcome these obstacles presented by HIV
diversity and cryptic epitope recognition might be to utilize a vaccine
consisting of more than one envelope sequence. In fact, a bivalent
approach has already been investigated in humans for immunogeni-
city (Kim et al., 2003; Thongcharoen et al., 2007). Such a vaccine,
when used in combination with a potent adjuvant formulation could
induce broader and stronger antibody responses than thosewhich can
be generated through the use of a single antigen in a weaker adjuvant.
Multivalent approaches including from 2 to over 50 separate antigens
have been investigated with some demonstrated increases in
neutralization breadth over monovalent immunization in direct
comparisons (Chakrabarti et al., 2005; Cho et al., 2001; Ljungberg et
al., 2002; Seaman et al., 2005, 2007; Wang et al., 2006). These, along
with additional multivalent studies, however, have shown mainly
increases in neutralizing breadth to tier 1 viruses with somewhat
limited success against more relevant tier 2 isolates (Azizi et al., 2008;
Pal et al., 2005, 2006; Wang et al., 2008; Zhan et al., 2005). Only a
subset of these studies have investigated the differences in antibody
epitopes between the polyvalent and monovalent approaches (Chak-
rabarti et al., 2005; Rollman et al., 2004). We ﬁrst described the
immunogenicity and protective efﬁcacy of the SF162 o-gp140ΔV2
glycoprotein in monkeys (Barnett et al., 2001; Cherpelis et al., 2001)
and recently described the puriﬁcation and characterization of the
clade C TV1 o-gp140ΔV2 Env (Srivastava et al., 2008). To further
assess the potential for boosting antibody potency and breadth, as
well as the epitopes involved, we also investigated the effect of
bivalent Env vaccines consisting of the trimeric proteins SF162 o-
gp140ΔV2 and TV1 o-gp140ΔV2 and compared these to approaches
containing a single envelope immunogen.
Results
Immunization of rabbits with trimeric o-gp140ΔV2 proteins derived
from subtype B and C HIV-1 strains in MF59 with or without CpG ODN
elicits high titer antigen-speciﬁc antibody responses
Groups of rabbits were immunized with trimeric SF162 o-
gp140ΔV2 (subtype B) and TV1 o-gp140ΔV2 (subtype C) Env proteins
either separately or together in MF59 with or without the addition of
CpG ODN as described in Materials and methods. Serum envelopeFig. 2. Neutralization of SF162 by immunized rabbit sera. Two weeks following the second
neutralizing activity against SF162. Individual serawere assayed and the geometric mean 80%
(center panel), or both proteins (right panel). P values for the differences between groupstiters were measured throughout the course of immunization. All
immunization formulations, including those comprised of SF162 Env
as well as those that contained TV1 Env, were able to elicit high titers
of SF162 Env-speciﬁc antibodies as determined by ELISA using the
SF162 o-gp140ΔV2 protein (Fig. 1A, top panel). Serum titers to SF162
Env were not signiﬁcantly different following a third or fourth protein
administration (PN0.05). As a group, rabbits immunized with the
homologous SF162 Env inMF59with CpG (SF162/MF59/CpG) elicited
the highest titers of binding antibodies. This vaccine, elicited
signiﬁcantly higher titers than the vaccine formulated without CpG,
SF162/MF59 (P=0.0015, p4). Interestingly, immunization with the
subtype C TV1 Env also resulted in the generation of SF162-speciﬁc
antibody responses, albeit at lower titers than those generated by the
homologous antigen (Fig. 1A, top panel). As found for SF162
immunization, the group immunized with TV1 Env in MF59/CpG
(TV1/MF59/CpG) also showed increased SF162 titers over those
rabbits immunizedwith TV1 plusMF59 (TV1/MF59) (P=0.0019, p4).
The combination of SF162 and TV1 Env antigens also elicited high
titers of SF162-speciﬁc antibodies. For the bivalent groups, the
inclusion of CpG did not signiﬁcantly improve the antibody response
over using MF59 alone (P=0.47, p4). However, bivalent immuniza-
tion did elicit higher titers than the TV1 monovalent groups
(P=0.0098 group 3 vs. 5 and group 4 vs. 6, p4).
TV1 Env-speciﬁc antibodies were also elicited by all immunization
regimens (Fig. 1A, bottom panel). Just as the SF162/MF59/CpG group
elicited the highest SF162 titers, the homologous TV1/MF59/CpG
group elicited the highest titers of TV1 o-gp140ΔV2 antibodies. TV1/
MF59/CpG serum titers were signiﬁcantly enhanced as compared to
the TV1/MF59 group (P=0.0013, p4). Similar to that found above, the
addition of CpG to the SF162 formulation increased titers to the TV1
Env as compared to SF162/MF59 (Pb0.0001, p4). However, CpG did
not signiﬁcantly enhance TV1 binding titers in the bivalent Env
regimen (P=0.12, p4). Bivalent immunization showed improved
TV1-speciﬁc titers as compared to immunizing with SF162 Env alone
(P=0.0011 group 1 vs. 5, P=0.0004 group 2 vs. 6, p4) but did not
enhance serum titers over the TV1 monovalent approach (P=0.32
group 3 vs. 5, P=0.22 group 4 vs. 6, p4).
To evaluate the conformation dependency of antibody binding,
we compared the total serum antibody titers to those measured
against denatured and reduced SF162 Env. The ratios of total
antibody titers to linear antibody responses were calculated and are
shown in Fig. 1B. Following a fourth immunization, the ratio of
total/linear antibodies decreases for all groups, except for rabbits
receiving the SF162/MF59/CpG vaccine. This indicates that for the
other ﬁve vaccines, a fourth administration leads to an increase in
antibodies that recognized linear epitopes. Interestingly, the CpG-
formulated vaccines also elicited higher levels of these linear
epitope antibodies. Whether the reason for this is due to a direct
effect of CpG binding to the antigen or an effect upon immune(p2), third (p3), and fourth (p4) immunizations, sera were assayed in TZM-bl cells for
(ID80) titers against SF162 are shown for sera immunized with SF162 (left panel), TV1
immunized in MF59 (●) or MF59+CpG (■) are listed for each time point.
Fig. 3. Bivalent immunization increases SF162 neutralization titers. Geometric mean ID80 neutralization titers against SF162 are shown for the indicated time points from
immunizations with MF59 (left panel) or MF59+CpG (right panel) with SF162 (■), TV1 (●), or both proteins (▴). P values for the differences between monovalent and bivalent
immunization are listed above the graphs. (B) SF162, (C) TV1.
Table 1
Peptide mapping of rabbit sera following four immunizations (p4)
Immunization
group
Serum titers
(log)a
Inhibition of neutralization (%)b
V3t V3c V4 V1t V1c V3t V3c V4 V5 V3s 4E10 b12
SF162 (MF59) 3.7 4.4 2.8 2 −1 20 46 28 4 0 −6 0
SF162 (MF59+CpG) 4.2 4.7 2.8 11 11 35 53 37 6 0 −8 4
TV1 (MF59) 3.9 4.5 2.7 4 0 73 76 24 10 1 −3 2
TV1 (MF59+CpG) 4.1 4.7 2.9 −1 1 76 95 24 10 2 −8 3
SF162+TV1 (MF59) 4.1 4.6 2.7 1 −1 68 74 38 26 0 −2 3
SF162+TV1 (MF59+
CpG)
4.2 4.9 3.0 −1 2 35 44 16 8 −2 −6 1
a Peptide-speciﬁc titers of serum antibodies were measured by ELISA.
b Values indicate the percentage of HIV-1 neutralization that is inhibited by the
presence of the indicated peptide at a serum dilution that corresponds to the ID70. Data
are from a representative experiment performed in duplicate. (t) tip, (c) cyclic, (s)
scramble.
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remains to be determined.
To obtain an estimate of antibody maturation, the avidity of
SF162 Env-speciﬁc serum antibodies was measured using an
ammonium thiocyanate ELISA (Fig. 1C). Antibody avidity was
similar following three or four immunizations (PN0.05 all groups),
although some increases were observed for the monovalent regi-
mens between these two time points, while antibody avidity
decreased using bivalent protein administration. Four immuniza-
tions with SF162/MF59/CpG elicited serum antibodies with the
highest avidity. Formulation with CpG increased avidity when SF162
was used as the antigen (P=0.014) but not when TV1 (P=0.79) or
the combination of Envs (P=0.72) was employed. Although immu-
nizing with TV1 yielded SF162-speciﬁc antibodies with moderate
avidity, this was improved by including SF162 in the vaccine
(P=0.022 group 3 vs. 5, P=0.015 group 4 vs. 6). However, the
bivalent approach yielded antibodies that were not distinguishable
in avidity to those elicited by SF162 (P=0.60 group 1 vs. 5, P=0.13
group 2 vs. 6).
Immunization of rabbits with trimeric o-gp140V2 proteins in MF59 with
CpG ODN results in enhanced neutralizing activity against SF162
Sera from each immunization group was tested for the capacity to
neutralize the SF162 pseudovirus in the TZM-bl assay (Li et al., 2005;
Monteﬁori, 2004). Each immunization group elicited high levels of
neutralizing antibodies to SF162 (Fig. 2). Substantial increases in the
geomean 80% neutralization titers (ID80 titers) were observed
between the second and third protein administrations that were
statistically signiﬁcant for all groups (Pb0.05) except SF162/MF59
(P=0.14). An additional fourth immunization further increased
neutralizing titers, albeit at levels that were only signiﬁcantly higher
for the SF162/TV1/MF59 group (P=0.048). Following the fourth
immunization, the bivalent regimen using MF59 and CpG elicited the
highest SF162 neutralization titers.
The inclusion of CpG led to increased neutralizing antibody
activity for all three immunization regimens. In rabbits where SF162
Env was used as the lone protein antigen, the addition of CpG
increased the ID80 titers from 3.3 to 4.4-fold as compared to using
MF59 alone (Fig. 2, left panel). This increase was statistically signi-
ﬁcant at each time point tested, with the largest increase observed
when comparing the p2 sera. Formulating with CpG also led to
higher SF162 neutralization titers when the heterologous TV1 Env
was used as antigen. These increases were also found to be signi-
ﬁcant at each time point examined (Fig. 2, middle panel). In contrast,
the inclusion of CpG did not signiﬁcantly increase neutralization
titers when the bivalent regimen was used following two adminis-
trations (P=0.22) (Fig. 2, right panel). However, following the third
and fourth immunizations, the addition of CpG did increase theSF162 ID80 titers signiﬁcantly (P=0.017 and Pb0.023, respectively)
over MF59 alone.
Immunization with a combination of subtype B and C envelope in MF59
elicits high levels of SF162 neutralizing titers
The combination of SF162 and TV1 Envs in MF59 resulted in higher
titers of SF162 neutralization than when either single Env was used
with MF59, despite the fact that in the bivalent regimen only half the
amount of each protein (12.5 μg) was administered as compared to
the monovalent cases (25 μg). This increase in ID80 SF162 titers was
observed as early as p2 protein boost (Fig. 3, left panel). For each time
point examined, the bivalent approach yielded statistically signiﬁcant
higher ID80 levels than using either SF162 or TV1 Env alone in MF59.
Interestingly, this effect was not observed when the immune
potentiator CpG was included (Fig. 3, right panel). SF162 ID80 titers,
in this case, were not signiﬁcantly improved until following the fourth
protein administration and then only compared to the monovalent
SF162/MF59/CpG regimen.
Neutralizing activity of SF162-speciﬁc antibodies elicited by envelope
immunization maps primarily to V3 and V4 regions
Since sera from each group of immunized rabbits contained high
levels of antibodies to SF162 Env, we next wanted to determine the
contribution due to variable loop-speciﬁc antibodies. Serum from
each immunization group was analyzed for V4 and V3 binding
antibodies via peptide ELISA. Rabbits from all immunization groups
exhibited recognition of a cyclic V4 peptide (Table 1). Each antigen
and adjuvant combination elicited similar, albeit relatively low, V4
titers. In a similar manner, serum samples were analyzed against
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consisted of a short region of the SF162 V3 loop that included the
GPGR motif with ﬂanking sequences (see Materials and methods).
The second peptide (V3c) encompassed the entire V3 sequence and
was cyclized via cysteine residues at each end. Recognition of the V3
tip peptide was observed for all immunized groups (Table 1). LargeFig. 4. Neutralization breadth. Values are the percentage of neutralization of viruses by sera
(bottom panel) in MF59 (●) or MF59+CpG (◯). Neutralization was carried out at a serumincreases in V3 antibodies were not observed between the third and
fourth administrations, therefore focus was placed on the post
fourth time point. In general, the inclusion of CpG had little effect
on the generation of V3 antibodies. The increase in V3 antibodies for
CpG-containing groups over non-CpG groups correlated with the
increase in overall titers observed for these groups. Interestingly,from rabbits immunized with SF162 (top panel), TV1 (center panel), or both proteins
dilution of 1:15. Numbers are the average of two experiments performed in triplicate.
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the homologous SF162/MF59 sera. In addition, bivalent immuniza-
tion generated a higher titer of V3 tip antibodies than either protein
alone in MF59. As for V3 cyclic recognition, the bivalent approach
with CpG elicited higher titers than the SF162/MF59/CpG or TV1/
MF59/CpG regimens.
To determine the contribution of antibody speciﬁcity to the
underlying differences between the immunization groups in SF162
neutralizing capacity, epitope mapping was carried out. Using a
modiﬁcation of the TZM-bl assay, pooled group sera (p4) were
incubated with peptides corresponding to speciﬁc regions of the
SF162 Env and/or epitopes of the monoclonal antibodies 4E10 and
IgGb12 (Table 1). Both SF162 and TV1 antigens were capable of
generating SF162 V3-speciﬁc neutralizing responses. High levels of
neutralization inhibition were observed using both the V3t and V3c
peptides. Interestingly, neutralization by sera from the TV1/MF59/
CpG immunized rabbits could be almost entirely blocked using the
V3c peptide. This indicates that the TV1 Env was capable of eliciting
antibodies that efﬁciently recognized the V3 region of SF162. Outside
of the GPGR/Q motif, the V3 loops of these two Envs differ by six
amino acids, with only one considered a non-conservative substitu-
tion (see sequences in Materials and methods). Whether this increase
is due to the conformational nature of the V3 sequence or simply the
inclusion of additional epitopes in the larger peptide remains unclear.
However, in the case of SF162 neutralization, this does not seem to be
a unique trait as we also observed increases when using the V3c
peptide against SF162 immunized rabbit sera. Each group also
contained neutralizing antibodies that recognized the regions corre-
sponding to V4. Some groups also contained low levels of V5
neutralizing antibodies. Only the SF162/MF59/CpG immunized
group exhibited inhibition by V1 peptides above background levels.
When comparing groups immunized with the same Env component
(s), the inclusion of CpG resulted in some shifting of the neutralizing
epitopes. For example, when SF162 Env was the immunogen, the CpG-
containing group recognized V1 as compared to the SF162/MF59
group. For the monovalent TV1 Env groups, the immune potentiator
CpG 7909 resulted in neutralizing activity that was increased in V3
cyclic recognition, but not V3 tip, as compared to the TV1/MF59
group. Inclusion of CpG in the bivalent regimen, however, led to a
decrease in V3, V4, and V5 neutralizing antibodies. No immunization
regimens elicited a signiﬁcant amount of neutralizing antibodies with
speciﬁcity for the 4E10 or b12 epitopes (Table 1). All groups were also
negative for neutralizing activity that was blocked by the control V3
scramble peptide.
Inclusion of subtype C envelope leads to an increase in neutralization
breadth over immunization with subtype B alone
We next assessed the capacity of these sera to neutralize a panel of
heterologous viruses. A variety of viruses was selected, including
viruses from a range of sensitive and resistant phenotypes, as well as
early isolates from the clade B panel (Li et al., 2005). Interestingly, the
peak of heterologous neutralization occurred following the third
immunization with neutralization breadth appreciably reduced
following the fourth injection (data not shown). Therefore, focus
was on the p3 time point and the percent virus neutralization for
these serum samples is shown (Fig. 4).
Overall, not one particular immunization regimen was found to be
vastly superior to another for eliciting a broadly neutralizing antibody
response. Against the most sensitive virus tested, IIIB, 73% (41/56) of
the serawere able to neutralize at a level of≥80%. Only two sera (both
in the TV1/MF59 group) were unable to neutralize IIIB at the 50% level
(Fig. 4, center panel). When speciﬁcally comparing the Env compo-
nent of the immunization, regardless of the adjuvant(s) involved, a
total of nine sera from each protein group were able to neutralize
SS1196 at ≥50%. Interestingly, neutralization of the dual tropic virus89.6 was most effective with sera from the subtype C TV1 Env groups
(Fig. 4, center panel). Eleven rabbits immunized with TV1 Env were
able to neutralize 89.6 at a level ≥50% while only six serum samples
from each of the SF162 and bivalent immunization groups neutralized
the same virus at this level. However, only a few sera, from the SF162
and bivalent groups, (sera 11, 15, 44, and 48–50) were able to
neutralize other clade B viruses (3988 and TRO) above the 50%
threshold (Fig. 4, top and bottom panels).
Neutralization of the clade C virus TV1.29 was observed from
samples that included the subtype C TV1 Env as part of the
immunization regimen (samples 31 and 39 from the TV1 Env groups
and sera 44, 46, 48, and 54 from the bivalent Env groups) (Fig. 4,
center and bottom panels). The other two clade C viruses tested were
not neutralized above the 50% level. No samples were able to
neutralize the clade A virus 461e2 at the 50% level.
To determine if we could increase the breadth observed for the
most broadly neutralizing sera, IgG from these samples was isolated to
increase the antibody concentration above that which could be
achieved using the 1:15 sera dilution. However, an IgG concentration
of up to 1 mg/ml did not show improvement in neutralization of
viruses that were below the 50% level (data not shown).
Discussion
This study was designed to test the effect of the immune
potentiator CpG 7909 on antibody responses when used in concert
with the delivery system MF59 in a glycoprotein HIV vaccine. In
addition, we sought to determine whether a combination of our well-
characterized trimeric Envs, SF162 o-gp140ΔV2 and TV1 o-gp140ΔV2,
from different subtypes would increase the titers and breadth of
antibody responses over a monovalent Env immunization scheme,
with speciﬁc interest in neutralizing responses. CpG 7909 was chosen
as it has previously been shown to act in synergy with MF59 to
enhance speciﬁc antibody responses to HIV-1 gag protein in mice
(O'Hagan et al., 2002). Although all immunization groups elicited high
antibody titers to both SF162 and TV1 envelopes, the inclusion of CpG
in the monovalent vaccine regimens boosted antibody titers between
2- and 3.8-fold to both SF162 and TV1 proteins. We did not
corroborate that this was a genuine CpG ODN effect by including, for
example, additional rabbit groups immunized with Env antigens and
non-CpG ODN. We reasoned that we could obviate these additional
experiments as rabbits have already been shown to be responsive to
the CpG 7909 immune stimulatory sequence (2006 equivalent
sequence) (Rankin et al., 2001). Interestingly, though, when compar-
ing bivalent immunization regimens, the boosting of antibody titers
with CpG was not statistically signiﬁcant.
Compared to immunization with a single antigen using either
MF59 or the combination of adjuvants, bivalent immunization
signiﬁcantly increased antibody titers to the individual heterologous
proteins. For example, SF162/TV1/MF59 elicited a greater response to
TV1 than did SF162/MF59. This result was not unexpected since we
had previously observed a similar effect when employing a DNA
prime/protein boost immunization strategy (Lian et al., 2005). The
current protein only bivalent immunization in MF59 was also able to
signiﬁcantly increase antibody titers to SF162 Env over immunization
with SF162/MF59. The underlying reason for this increase was not
readily predicted from peptide mapping studies. Linear and V3
epitopes were not increased relative to the increase seen in overall
titers to SF162, nor was antibody avidity signiﬁcantly increased.
However, there was a correlation between the increase in SF162 titers
and increases in avidity to SF162 for bivalent immunization groups as
compared to those containing TV1 as the single antigen. The CpG-
containing monovalent immunization regimens elicited higher SF162
titers than using MF59 alone. In the case of the SF162 monovalent
regimen, the addition of CpG signiﬁcantly increased antibody avidity
(P=0.0138, p4).
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our immunization regimens also signiﬁcantly increased the neu-
tralization titers against SF162. Similarly, a combination of the two
antigens derived from different subtypes in MF59 was able to elicit
a greater neutralizing antibody response as compared to using
either antigen individually. However, this neutralizing antibody
boosting effect observed with bivalent Env immunization was not as
obvious when CpG was included in the vaccine formulation.
Although bivalent immunization in MF59 resulted in signiﬁcantly
higher neutralizing titers than either monovalent protein in MF59,
beginning after the second administration, the addition of CpG
boosted neutralizing antibody titers from single antigen immuniza-
tion to the same levels as that obtained with both proteins with
CpG. For reasons unclear at this point, this particular formulation of
bivalent immunization along with MF59/CpG does not result in an
optimally synergistic response. Not until the fourth immunization
did we observe a signiﬁcant difference between neutralizing
antibody titers elicited by SF162/TV1/MF59/CpG and TV1/MF59/
CpG (P=0.026).
Although four immunizations boosted SF162 neutralizing titers,
neutralizing breadth was greatest following three administrations.
Interestingly, as breadth decreased between the third and fourth
immunization, so did the ratio of antibodies which recognized
conformational versus linear epitopes (Fig. 1B). However, it is
unclear at this time whether a bona ﬁde correlation exists between
these attributes. Additionally, the neutralizing antibody boosting
observed when CpG is included as a component of the vaccine did
not translate to an increase in the breadth of the neutralizing
response. The lone exception was in the case of the virus SS1196 as
SF162/MF59/CpG immunization did increase neutralization
(P=0.008). Interestingly, against the tier 2 clade B virus TRO,
neutralization was statistically better when CpG was not included in
the formulation. When comparing all three regimens, use of the
single adjuvant MF59 elicited elevated neutralization levels against
TRO (Pb0.05, all groups). For all other viruses, no substantial
difference was observed between immunizations based on adju-
vants. Although the levels are relatively low, evaluation of sera from
rabbits immunized with SF162 o-gp140ΔV2 in MF59 showed
improved neutralization of a subset of clade B viruses (TRJO, 3988,
TRO, WITO, and REJO) as compared to sera from TV1/MF59 rabbits
(Pb0.02). Overall, relatively few sera (7/58, no p3 sera for two
rabbits) were able to neutralize more than three of the viruses
tested at the 50% level or above. All seven sera neutralized IIIB,
SS1196, and 89.6. Four of these (sera 31, 39, 46, and 54) were also
able to neutralize TV1.29. The remaining three sera were able to
neutralize ﬁve total viruses, including 3988 and TRO (serum 15) or
TRO and TV1.29 (sera 44 and 48). Only one of these samples, sera
15, did not include the subtype C Env as part of the immunization
regimen.
One argument for eliciting antibodies with greater cross-
neutralization potential is to immunize with sequences representa-
tive of viruses from differing clades and thus increasing the number
of epitopes recognized as opposed to using a lone antigen that may
elicit strain-speciﬁc antibodies. For example, an examination of V3
loops from JRFL (clade B) and BR025 (clade C) showed that there
are intrinsic differences in the V3 loop conformations that are
localized to the stem and turn regions. It was predicted that this
could lead to subtype-speciﬁc neutralizing antibodies that would
limit cross-reactivity (Patel et al., 2008). In the current study,
viruses from both subtypes B and C were able to be neutralized by
some sera from rabbits whose immunization regimen contained the
TV1 Env. Although many of these sera are from bivalently
immunized rabbits, some are from rabbits immunized only with
the TV1 antigen. TV1 contains a V3 loop with a GPGQ motif as
opposed to the GPGR sequence found in SF162. Other studies have
suggested that clade A viruses which contain the GPGQ V3 sequenceare superior for inducing antibodies with greater cross-neutralizing
activity than clade B viruses that include the GPGR motif (Gorny et
al., 2006; C. Krachmarov et al., 2005). Similarly, using a chimeric
SF162 virus expressing different V3 sequences, an analysis of V3
antibodies from clade A and B viruses found that anti-V3A
antibodies were able to neutralize more V3 sequences than anti-
V3B antibodies (Krachmarov et al., 2006). Additionally, an immuni-
zation study using a gp120 DNA/V3 fusion protein boost regimen
determined that antibodies elicited by GPGQ non-clade B sequences
were able to neutralize viruses with both GPGQ and GPGR motifs
(Zolla-Pazner et al., 2008). It was determined that antibodies
elicited by GPGR viruses favored GPGR neutralization and suggested
that GPGR may be dominant over GPGQ when combined for
immunization (Zolla-Pazner et al., 2008). In the current study,
immunization with the GPGQ TV1 did lead to better breadth than
the GPGR SF162 regimen, but bivalent immunization resulted in the
greatest cross-neutralizing activity. However, our study used o-
gp140ΔV2 Env while the previous study speciﬁcally focused on the
V3 epitope by using V3 fusion proteins for boosting. Unfortunately,
since the neutralizing breadth we observed was relatively low,
determination of the importance of the V3 epitope and its
relationship with cross-neutralizing activity was indeterminate.
Peptide mapping was employed to determine the underlying basis
for the differences observed in SF162 neutralization between the
immunization groups (Table 1). In view of the fact that the highest
neutralizing titers were found following the fourth immunization,
focus was placed on this time point for analysis. Between the two
protein antigens used in this study, TV1 o-gp140ΔV2 resulted in a
higher percentage of neutralization that was inhibited by V3 peptides.
Depending on the adjuvant(s) used, 73–76% of SF162 neutralization
by sera from TV1 immunized rabbits was blocked by the V3 tip
peptide as compared to 35% for SF162 immunization. This was
accompanied by an increase in V3 tip ELISA titers for TV1/MF59 as
compared to SF162/MF59. When CpG was included though, an
increase in ELISA titers was not observed. Inclusion of CpG did not
effect the SF162 neutralization epitopes for TV1 immunization.
Similarly, sera from SF162 immunizationwith CpG contained a similar
level of V3 neutralizing activity as compared to MF59 alone despite
the V3 ELISA titers tripling. There was, however, a small amount of
neutralization that was inhibited by V1 peptide.
Previous studies in macaques using the SF162 o-gp140ΔV2
construct have reported the elicitation of a high percentage of
neutralizing antibodies that recognize the V1 region (Derby et al.,
2006). In the current study (conducted in rabbits), V1 neutralizing
antibodies were observed at low levels while there was found to be a
high level of neutralization due to antibodies of V3-speciﬁcity. In
contrast, Derby et al. detected only low levels of these V3 neutralizing
antibodies. The results in macaques are in agreement with results we
have obtained in vaccinated humans where neutralizing antibodies to
V1 were detected, but only low levels of V3-speciﬁc neutralizing
antibodies were found (Barnett, unpublished data). In addition, in
recent non-human primate studies, both V1 and V3 binding and
neutralizing antibodies were detected (Burke and Barnett, unpub-
lished data). It is important to note that there are several key
differences between these studies, most notably, which are the
immunization strategies (protein only vs. prime/protein boost),
routes of immunization, as well as the subjects (rabbits, macaques,
and humans). However, we have also observed differences in the
neutralizing antibody epitopes elicited between rabbits and mice
when using the same immunogen (Brian Burke, Susan Barnett, Gib
Otten, and Hong Liu, unpublished data). Additionally, although we
observed that CpG was able to boost the neutralizing antibody
response to SS1196 in the SF162 Env immunization regimen, this is in
contrast to results observed in a study by Shu et al. where boosting of
antibody responses was not observed when using CpG as compared to
MF59 alone in the protein boost phase (Shu et al., 2007). However,
154 B. Burke et al. / Virology 387 (2009) 147–156this study was completed in guinea pigs using an adenovirus or DNA
prime/SF162 Env boost scheme. All of these results indicate that
further study must be done on the effect of priming and adjuvant
combinations as well as which species to use for in vivo studies and
how predictive these results are as compared to neutralizing antibody
epitopes elicited in humans.
Although the precise mechanisms of adjuvant action for CpG
7909 and MF59 are still subjects of intensive research, ample
evidence suggests that CpG 7909/2006 activates B cells and
increases production of costimulatory molecules in plasmacytoid
dendritic cells while MF59 interacts with macrophages and mono-
cytes and is internalized at the site of intramuscular injection
(Dupuis et al., 1998; Kerkmann et al., 2003; Seubert et al., 2008). By
acting on the innate immune system via increased endocytosis and
antigen uptake as well as enhanced dendritic cell maturation, these
adjuvants should lead to a robust priming of the adaptive immune
response. It is therefore not surprising that the combination of both
adjuvants enhances the immunogenicity of a bivalent HIV vaccine
administered intramuscularly. Importantly, both CpG 7909 and
MF59 are licensed for human use and have been well tolerated in
clinical trials, including hepatitis B vaccine and inﬂuenza vaccine
trials performed in people living with HIV (Cooper et al., 2004,
2005; Gabutti et al., 2005; Kahn et al., 1994; Ott et al., 1995). A
continuing goal of HIV vaccine development is to achieve high
avidity functional neutralizing antibodies following the delivery of
Env protein antigens. The present ﬁndings indicate that using a
multivalent methodology along with the synergistic combination of
adjuvants MF59 and CpG can enhance humoral responses against
HIV-1. However, optimization of adjuvantation, while necessary for
improving neutralizing potency, was not sufﬁcient here for accessing
all critical epitopes required for generating the desired neutraliza-
tion breadth believed to be required for an effective HIV vaccine. As
enhancing the quality of antigen-elicited immune responses is
critical for the development of future vaccines against HIV and other
infectious diseases, these results highlight the continued need for
further investigations of not only adjuvants and combinations of
adjuvants, but also of novel vaccine regimens, diverse antigens and
antigen structures, and combinations thereof.
Materials and methods
Proteins, adjuvants, and immunization of rabbits
Six groups of ten New Zealand White rabbits each were used in
this immunogenicity study. Animals in groups 1 and 2 were
immunized with subtype B SF162 o-gp140ΔV2, groups 3 and 4
with subtype C TV1 o-gp140ΔV2, and groups 5 and 6 with both
subtype B and C proteins. The clade B protein was puriﬁed from
the CCR5 tropic strain SF162 and contained a 30 amino acid
deletion in the V2 loop region as previously described (Srivastava
et al., 2003). In a similar manner, the clade C TV1 Env was also
prepared and puriﬁed as previously described (Lian et al., 2005).
Four protein immunizations were administered intramuscularly, in
the gluteus, at weeks 0, 4, 12, and 24. Total protein dosage at each
immunization was 25 μg. Protein was administered in MF59
(groups 1–6). Groups 2, 4, and 6 also contained 500 μg CpG-7909
(Coley Pharmaceutical Group, Inc., Ottawa, Canada). Serum samples
were collected prior to each immunization and two weeks following
each immunization.
Envelope-speciﬁc antibody titers in rabbit sera
Envelope-speciﬁc serum total antibody titers were quantiﬁed by a
standard ELISA assay as previously described (Srivastava et al., 2002).
To determine antibody responses against linear envelope epitopes,
ELISA was carried out using SF162 Env protein which was denaturedand reduced according to previous methods (Sharma et al., 2006;
Srivastava et al., 2002). To determine the antibodies induced against
the variable region epitopes of envelope, anti-peptide ELISA was
performed. The responses against V3 and V4 of SF162 Env were
measured using the peptides V3 tip, V3 cyclic, and V4 cyclic and
methods previously described (Sharma et al., 2006; Srivastava et al.,
2002).
Antibody avidity measurements
Antibody avidity index determination was performed using an
ammonium thiocyanate (NH4SCN) displacement ELISA as described
elsewhere (Srivastava et al., 2002).
Assessment of HIV-1 neutralizing antibodies
Neutralization was assessed using molecularly cloned pseudo-
viruses and a luciferase reporter gene assay in TZM-bl cells (Dr John C.
Kappes, Dr Xiaoyun Wu and Tranzyme, Inc.(Durham, NC)) as
described previously (Li et al., 2005; Monteﬁori, 2004). Brieﬂy, a
total of 200 TCID50 pseudovirus/well were added to diluted sera
samples and incubated at 37 °C for 1 h. Following incubation, 10,000
cells/well in DEAE-dextran-containing media were added and
incubated for 48 h at 37 °C. The ﬁnal concentration of DEAE-dextran
was 10 μg/ml. Single round of infection HIV-1 Env pseudoviruses were
prepared by co-transfection of 293T cells with an envelope expression
plasmid containing a full-length gp160 env gene along with an env-
deﬁcient HIV-1 backbone vector (pSG3Δenv), using TransIT®-LT1
transfection reagent (Mirus Bio Corp., Madison, WI), as previously
reported (Lian et al., 2005). After 48 h, the cell culture supernatant
containing the pseudovirus was ﬁltered through a 0.45 μm ﬁlter.
Neutralizing activity was measured as reductions in luciferase gene
expression. The percent reduction in relative luminescence units
(RLU) was calculated relative to the RLU in the presence of pre-
immunization serum. Neutralizing antibody titers against SF162 were
determined using 3-fold serially diluted sera samples. The breadth of
neutralizing antibodies in sera was assessed at a serum dilution of
1:15. The percent neutralization was corrected for non-speciﬁc
inhibition using the formula described previously with MLV as a
control virus (Kothe et al., 2007).
Neutralizing antibody epitope mapping
Mapping of neutralizing epitopes was done using the TZM-bl assay
with a few modiﬁcations. An additional incubation of peptide with
diluted serum samples was carried out for 1 h at 37 °C prior to the
addition of virus. The dilution of serum used was that corresponding
to the ID70. The concentration of peptide after addition to serumwas
15 μg/ml. Peptides corresponding to regions of the SF162 Env used for
epitope mapping were V1 tip (TNLKNATNTKSSNWKEMDRGEIK), V1
cyclic (CTNLKNATNTKSSNWKEMDRGEIKNC), V3 tip (CTRKSITIGP-
GRAFYC), V3 cyclic (CTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHC),
V4 cyclic (CNSTQLFNSTWNNTIGPNNTNGTITLPC), and V5 (TRDAG-
KEISNTTEIFR). The control peptide was V3 scramble (TRKSFYATP-
GRAITIG). Peptides corresponding to the epitopes of the monoclonal
antibodies 4E10 (NWFDITNWLWYIKKKK) (Brunel et al., 2006) and
b12 (NWPRWWEEFVDKHSSC) (Boots et al., 1997) were also used. All
peptides were obtained from Sigma-Genosys (The Woodlands, TX).
Statistical analyses
The Mann Whitney test was used to test for differences between
immunization groups. For all comparisons, a two-sided Pb0.05 was
considered statistically signiﬁcant. Statistical analyses were per-
formed using the analysis software within the GraphPad Prism
package 5.01.
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